Addendum

Olaparib (prostate cancer) – Addendum to Commission A23-03

Report documents

Indication:

Adults with metastatic castration-resistant prostate cancer (mCRPC) in whom chemotherapy is not clinically indicated

Result of dossier assessment:

Patients with treatment-naive mCRPC and BRCA mutation: hint of major added benefit
Patients with treatment-naive mCRPC without BRCA mutation (BRCA wild type): hint of lesser benefit
Patients with pretreated mCRPC: added benefit not proven

2023-07-06 A G-BA decision was published.

Project no.: A23-47
Commission: Commission awarded on 23.05.2023 by the Federal Joint Committee (GBA).
Report type: Addendum
Status: Commission completed
Department/Division: Drug Assessment
Topic: Cancer
Note: If the need for additional work on a project commissioned by the GBA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.

Press contact

+49 221 356850

press@iqwig.de

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.